- Home
- CDIO vs IGC Comparison
CDIO vs IGC Comparison
Compare CDIO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- IGC
- Stock Information
- Founded
- CDIO 2017
- IGC 2005
- Country
- CDIO United States
- IGC United States
- Employees
- CDIO N/A
- IGC N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- IGC Health Care
- Exchange
- CDIO Nasdaq
- IGC Nasdaq
- Market Cap
- CDIO 23.6M
- IGC 19.1M
- IPO Year
- CDIO N/A
- IGC N/A
- Fundamental
- Price
- CDIO $0.33
- IGC $0.28
- Analyst Decision
- CDIO Buy
- IGC Strong Buy
- Analyst Count
- CDIO 1
- IGC 2
- Target Price
- CDIO $2.00
- IGC $3.88
- AVG Volume (30 Days)
- CDIO 807.0K
- IGC 415.4K
- Earning Date
- CDIO 05-14-2025
- IGC 02-18-2025
- Dividend Yield
- CDIO N/A
- IGC N/A
- EPS Growth
- CDIO N/A
- IGC N/A
- EPS
- CDIO N/A
- IGC N/A
- Revenue
- CDIO $34,890.00
- IGC $1,236,000.00
- Revenue This Year
- CDIO $1,434.82
- IGC N/A
- Revenue Next Year
- CDIO $4,661.91
- IGC $18.34
- P/E Ratio
- CDIO N/A
- IGC N/A
- Revenue Growth
- CDIO 104.45
- IGC 1.65
- 52 Week Low
- CDIO $0.19
- IGC $0.26
- 52 Week High
- CDIO $1.77
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- CDIO 35.24
- IGC 40.22
- Support Level
- CDIO $0.30
- IGC $0.29
- Resistance Level
- CDIO $0.40
- IGC $0.32
- Average True Range (ATR)
- CDIO 0.05
- IGC 0.02
- MACD
- CDIO -0.01
- IGC -0.00
- Stochastic Oscillator
- CDIO 21.16
- IGC 2.50
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.